Supriya Lifescience Revenue Jumps 18.86% to ₹827.8 Cr, Recommends ₹1 Dividend

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
Supriya Lifescience Revenue Jumps 18.86% to ₹827.8 Cr, Recommends ₹1 Dividend
Overview

Supriya Lifescience reported an 18.86% rise in revenue to ₹827.875 crore and an 11.26% profit increase to ₹209.12 crore for the fiscal year 2026. The company's board has recommended a final dividend of ₹1 per share.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Supriya Lifescience Reports Strong FY26 Performance

Supriya Lifescience Limited announced its audited financial results for the fiscal year ended March 31, 2026. The company achieved a consolidated revenue from operations of ₹827.875 crore, representing an 18.86% increase compared to ₹696.485 crore in the previous fiscal year.

Net profit for FY26 grew by 11.26% to ₹209.12 crore, up from ₹187.958 crore in FY25. The board has recommended a final dividend of ₹1.00 per equity share, subject to shareholder approval at the upcoming Annual General Meeting.

Financial Highlights for FY26

The company's revenue growth reflects continued expansion in its pharmaceutical ingredients business. The increase in net profit demonstrates improved profitability. An unmodified audit opinion was issued, indicating sound financial reporting and governance.

Impact of New Labour Codes

Supriya Lifescience noted an incremental employee benefit cost of ₹0.458 crore for FY26, attributed to the implementation of new labour codes that became effective from November 21, 2025. While this cost is currently minor, its potential impact on future operating expenses and margins will be a factor to monitor.

Peer Landscape

While direct peer comparison data for FY26 was not provided, Supriya Lifescience's performance is within the context of the active pharmaceutical ingredient (API) manufacturing sector in India. Competitors in this space include companies like Divi's Laboratories, Laurus Labs, and Aarti Drugs.

Key Metrics

  • FY26 Revenue: ₹827.875 crore (up 18.86% from FY25)
  • FY26 Profit: ₹209.12 crore (up 11.26% from FY25)
  • Q4 FY26 Revenue: ₹276.528 crore
  • Q4 FY26 Profit: ₹74.229 crore
  • Recommended Dividend: ₹1.00 per share

Future Outlook

Investors will be watching for the continuation of this growth momentum in upcoming quarters. The company's ability to manage operating costs, particularly in light of evolving labour regulations, will be key. Dividend trends and any future corporate actions will also be important indicators for shareholders.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.